EP2793816A2 - Associations de principes actifs à base d'un ou de plusieurs polyols et d'un ou de plusieurs acides hydroxamiques physiologiquement acceptables, ainsi que préparations cosmétiques ou dermatologiques contenant de telles associations de principes actifs - Google Patents

Associations de principes actifs à base d'un ou de plusieurs polyols et d'un ou de plusieurs acides hydroxamiques physiologiquement acceptables, ainsi que préparations cosmétiques ou dermatologiques contenant de telles associations de principes actifs

Info

Publication number
EP2793816A2
EP2793816A2 EP12808786.3A EP12808786A EP2793816A2 EP 2793816 A2 EP2793816 A2 EP 2793816A2 EP 12808786 A EP12808786 A EP 12808786A EP 2793816 A2 EP2793816 A2 EP 2793816A2
Authority
EP
European Patent Office
Prior art keywords
preparations
polyols
cosmetic
glycol
molecular weights
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP12808786.3A
Other languages
German (de)
English (en)
Inventor
Andreas Firyn
Hülya GÖKSEL
Manuela Köhler
Bernd Traupe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beiersdorf AG
Original Assignee
Beiersdorf AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beiersdorf AG filed Critical Beiersdorf AG
Publication of EP2793816A2 publication Critical patent/EP2793816A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A61K8/345—Alcohols containing more than one hydroxy group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/08—Ethers or acetals acyclic, e.g. paraformaldehyde
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/005—Antimicrobial preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A61Q5/006—Antidandruff preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/52—Stabilizers
    • A61K2800/524—Preservatives

Definitions

  • the present invention relates to cosmetic drug combinations and preparations containing such drug combinations, as well as their use as effective against bacteria, mycota and viruses substances.
  • the healthy warm-blooded organism especially the healthy human skin, is populated with a variety of non-pathogenic microorganisms.
  • This so-called microflora of the skin is not only harmless, it represents an important protection against opportunistic or pathogenic germs.
  • Bacteria belong to the prokaryotic unicellular organisms. They can be roughly distinguished according to their shape (sphere, cylinder, curved cylinder) and the structure of their cell wall (gram-positive, gram-negative). Finer subdivisions also take into account the physiology of the organisms. There are aerobic, anaerobic and facultatively anaerobic bacteria. Some individuals are of medical importance in their capacity as pathogenic agents, while others are completely harmless.
  • Antibiotics for example, which is not applicable to all antimicrobial substances, can be dated to the year 1941, although the first findings on penicillin were already found in 1929. Antibiotics in the modern sense are not for all medical, even not suitable for cosmetic applications because Often the warm-blooded organism, for example the sick patient, is impaired in its use in some way in its metabolic functions.
  • Gram-negative bacteria are, for example, Escherichia coli, Pseudomonas species and Enterobacteriaceae, such as Citrobacter.
  • Gram-positive bacteria also play a role in cosmetics and dermatology.
  • bacterial secondary infections are of etiological significance, among other influences.
  • One of the most important microorganisms associated with impure skin is Propionibacterium acnes.
  • Impure skin and / or comedones affect the well-being of those affected but even in mild cases. Since virtually every adolescent or person is affected by blemished skin of some kind, many people need to remedy this condition.
  • a particular object of the present invention was therefore to find a substance or combination of substances which is effective against impure skin or Propionibacterium acnes.
  • the present invention relates in a further embodiment cosmetic deodorants.
  • Such formulations serve to eliminate body odor, which arises when the per se odorless fresh sweat is decomposed by especially gram-positive microorganisms.
  • the usual cosmetic deodorants are based on different active principles.
  • liquid deodorants for example aerosol sprays, roll-ons and the like, as well as solid preparations, for example deodorant sticks ("sticks"), powders, powder sprays, intimate cleaners, etc.
  • antiperspirants can be prevented by astringents - mainly aluminum salts such as aluminum hydroxychloride (Aluchlorhydrat) - the formation of sweat.
  • Aluchlorhydrat aluminum hydroxychloride
  • the bacterial flora on the skin can be reduced. Ideally, only the odor causing microorganisms should be effectively reduced. In practice, however, it has been found that the entire microflora of the skin can be affected. The sweat flow itself is not influenced by this, ideally only the microbial decomposition of the sweat is temporarily stopped.
  • body odor can also be masked by fragrances, a method that is least in line with the consumer's aesthetic needs, as the mixture of body odor and perfume smells rather unpleasant.
  • Another object of the present invention was therefore to develop cosmetic deodorants which do not have the disadvantages of the prior art.
  • the deodorants should protect the microflora of the skin largely, but selectively reduce the number of microorganisms that are responsible for the body odor.
  • a further object was to develop cosmetic deodorants which harmonize with the widest possible variety of customary cosmetic auxiliaries and additives, in particular with the perfume ingredients which are especially important in deodorizing or antiperspirant formulations.
  • Yet another object of the invention was to provide cosmetic deodorants which are effective over a prolonged period, on the order of at least half a day, without noticeably reducing their effect.
  • Eucaryotes are organisms whose cells (Eucytes), unlike those of the so-called procaryotes (Procytes), have a nucleus delimited by the nuclear envelope and the nuclear membrane from the rest of the cytoplasm. The nucleus contains the genetic information stored in chromosomes.
  • mycobionts include, for example, yeasts (Protoascomycetes), molds (Plectomycetes), mildew (Pyrenomycetes), downy mildew (Phycomycetes), and wild mushrooms (Basidiomycetes).
  • Fungi are not plant organisms, but like these they have a cell wall, cell-filled vacuoles, and a microscopically visible plasma flow. They contain no photosynthetic pigments and are C heterotrophic. They grow under aerobic conditions and gain energy through oxidation of organic substances. However, some representatives, such as yeasts, are facultative anaerobes and capable of producing energy through fermentation processes.
  • Dermatomycoses are diseases in which certain types of fungi, in particular dermatophytes, invade the skin and hair follicles.
  • the symptoms of dermatomycoses include blisters, exfoliation, rhagades and erosion, usually associated with itching or allergic eczema.
  • Dermatomycoses can be subdivided essentially into the following four groups: dermatophytes (eg, epidermophytia, favus, microsporia, trichophytia), yeast mycoses (eg, pityriasis and other pityrosporum-related mycoses, candidal infections, blastomycosis, Busch-Buske disease, torulosis, Piedra alba, torulopsidosis, tricho- sporosis), mold mycoses (eg aspergillosis, cephalosporidosis, phycomycosis and scopular isopidemosis), systemic mycoses (eg chromomycose, coccidiomycosis, histoplasmosis).
  • dermatophytes eg, epidermophytia, favus, microsporia, trichophytia
  • yeast mycoses eg, pityrias
  • the pathogenic and facultative pathogens include, for example, Candida species (for example Candida albicans) and those of the family Pityrosporum from the group of yeasts.
  • the involvement of Pityrosporum ovale in the development of psoriasis is discussed by experts.
  • An object of the present invention was to obviate the drawbacks of the prior art and to provide substances and preparations containing such substances, by the use of which the formation of dandruff is prevented, the physiological skin flora not suffering any significant losses.
  • topically administered antibiotics have the disadvantage that they not only rid the skin flora of the secondary pathogen, but also severely impair the physiological skin flora and the natural healing process is slowed down in this way again.
  • the object of the present invention was to eliminate the disadvantages of the prior art and to provide substances and preparations containing such substances, by the use of which superinfections can be cured, wherein the physiological skin flora suffers no appreciable losses.
  • Protozoa are parasitically living unicellular organisms with clearly delineated nucleus that reproduce asexually (by dividing into two or four divisions and budding) or sexually (gameto-, gamonto- and autogamy).
  • the food intake from the environment takes place by permeation and by Pino- or phagocytosis.
  • motile state forms in addition to vegetative, mostly motile state forms (so-called trophozoites), most protozoa can also form cysts as permanent forms under unfavorable circumstances.
  • protozoa are subdivided into four different groups:
  • Parasitic protozoa are often transmitted in subtropical and tropical areas by stinging and sucking insects, but also by dirt and smear infection and through the food chain.
  • Some medically and dermatologically relevant protozoonoses are: trichomoniasis (caused by Trichomonas vaginalis), Lamblia (caused by Lamblia intestinalis), visceral and cutaneous and mucosal leishmaniasis (caused for example by Leishmania donovanii, L. tropica, L. braasiliensis, L mexicana, L. diffusa or L.
  • trypanosmiasis caused by various species of trypanosomes
  • amoebic dysentery and amebiasis caused, for example, by various Entamoeba species, Jodamoeba butschlii or Naegleria fowleri
  • coccidosis by Isospora belli
  • Balantidenruhr caused by Balantidium coli
  • Protozoan-induced medical and dermatological phenomena affect, in some cases substantially, human well-being. There is therefore a significant need for the persons concerned to remedy this situation.
  • An object of the present invention was thus to find active principles against protozoa.
  • viruses In contrast to the prokaryotic and eukaryotic cellular organisms, viruses [lat. Poison] are biological structures that require a host cell for biosynthesis. Extracellular viruses (also called “virions”) consist of a single-stranded or double-stranded nucleic acid sequence (DNA or RNA) and a protein coat (called capsid), optionally surrounded by an additional lipid-containing envelope (Envelope). The classification of viruses was classed according to clinical criteria, but nowadays mostly according to their structure, their morphology, but in particular according to the nucleic acid sequence.
  • influenza viruses family of Orthomyxoviridae
  • lyssaviruses e.g., rabies, family of rhabdoviruses
  • enteroviruses e.g., hepatitis A, family Picornaviridae
  • hepadnaviruses e.g., hepatitis B, family Hepadnaviridae
  • Viruzide ie virus killing substances in the true sense does not exist because viruses do not have their own metabolism. It was therefore also discussed whether viruses should be classified as living things. At any rate, pharmacological interventions without damaging the unaffected cells are difficult. Possible mechanisms of action in the fight against the viruses are primarily the disruption of their replication, for example by blocking the enzymes which are important for replication and which are present in the host cell. Furthermore, the release of the viral nucleic acids into the host cell can be prevented.
  • antiviral or “effective against viruses”, “virucidal” or the like understood the property of a substance to protect a single or multicellular organism, whether prophylactically or therapeutically, from harmful consequences of a viral infection, regardless of what actual mechanism of action of the substance in an individual case is.
  • preservatives are, for example, the compounds known as parabens, in particular 4-hydroxybenzoic acid and its esters, methylparaben, ethylparaben, propylparaben, isopropylparaben, butylparaben, isobutylparaben, phenylparaben.
  • Hydroxamic acids are a class of chemical compounds containing the grouping -CO-NHOH as a functional group.
  • An example is the octanohydroxamic acid, also called caprylohydroxamic acid, which is characterized by the following structure.
  • the polyols can be advantageously chosen from the group of at least bifunctional alcohols. Particularly advantageous are the polyols selected from the following group:
  • Ethylene glycol polyethylene glycols having molecular weights of up to about 2,000, propylene glycol-1,2, polypropylene glycols-1,2 with molecular weights of up to about 2,000, propylene glycol-1,3, polypropylene glycols-1,3 with molecular weights of up to about 2,000 , Butylene glycol-1, 2, polybutylene glycol-1, 2 having molecular weights of up to about 2,000, butylene glycol-1, 3, polybutylene glycol-1, 3 having molar masses up to about 2,000, butylene glycol-1, 4, polybutylene glycol-1 , 4 with molecular weights up to about 2,000, butylene glycol-2,3, polybutylene glycol-2,3 with molecular weights up to about 2,000, ⁇ , ⁇ -alkanediols, glycerol, diglycerol, triglycerol, tetraglycerol and pentaglycerol, wherein the
  • Very preferred polyols are selected from the group of vicinal diols, ie the 1, 2-alkanediols. Among these, in turn, are preferably 1, 2-pentanediol, 1, 2-hexanediol. 1, 2-heptanediol, 1, 2-octanediol. 1, 2-nonanediol and 1, 2-decanediol.
  • the weight ratios of hydroxamic acid, in particular octanohydroxamic acid, on the one hand to the total amount of one or more polyols on the other hand from the range of 1 to 10 to 10 to 1, preferably from 1 to 5 to 5 to 1, particularly preferably from 1 to 2 to 2 to 1 to choose.
  • the active compound combinations according to the invention are used in cosmetic or dermatological preparations.
  • Preparations according to the invention advantageously contain 0.001 to 5.0% by weight of hydroxamic acid, in particular octanohydroxamic acid, preferably 0.01 to 2.0% by weight, based on the total weight of the preparations.
  • Preparations according to the invention advantageously contain from 0.001 to 5.0% by weight of one or more polyols, preferably from 0.01 to 2.0% by weight, in each case based on the total weight of the preparations.
  • the cosmetic and / or dermatological formulations according to the invention may be composed as usual and used for the treatment of the skin and / or the hair in the sense of a dermatological treatment or a treatment in the sense of nourishing cosmetics. But they can also be used in make-up products in decorative cosmetics.
  • the active compound combinations according to the invention the growth of Staphylococcus. Aureus prevent, and this in a synergistic way, so superadditive in relation to the individual components.
  • the active ingredients used in the invention the growth of Gram-positive and Gram-negative bacteria, mycocionts.
  • the active compounds used according to the invention are also suitable for use as deodorizing active ingredients in cosmetic deodorants and also against blemished skin, mild forms of acne or propionibacterium acnes.
  • the active compounds according to the invention are likewise suitable as being particularly effective against streptococci.
  • the active compounds used according to the invention can prevent the spoilage of organic substances, in particular cosmetic and dermatological preparations, by infestation with Gram-positive and Gram-negative bacteria, mycobionts and viruses when they are added to these preparations
  • the active ingredients used in the invention are optionally in a suitable cosmetic or dermatological carrier, brought into contact with the contaminated by Mycobionten area, and a method for the protection of organic products from infestation Mycobionts, characterized in that these organic products, the active ingredients used in the invention are added in an effective amount.
  • the active compound combinations according to the invention have excellent activity against mycobionts, in particular in their form of effect of the dermatomycoses.
  • the active compound combinations according to the invention are in particular capable of preventing the growth of yeasts, in particular of the Pityrosporum species, in particular Pityrosporum ovale. It has also surprisingly been found that the active compound combinations according to the invention prevent the formation of seborrheic phenomena, in particular dandruff, as well as eliminating already existing seborrheic phenomena, in particular dandruff.
  • the active compound combinations according to the invention can prevent spoilage of organic substances, in particular cosmetic and dermatological preparations, by infestation with mycobionts when added to these preparations.
  • the invention therefore also a method for combating mycobionts, characterized in that the active compound combinations according to the invention, optionally in a suitable cosmetic or dermatological carrier, are brought into contact with the contaminated by Mycobionten area, and a method for the protection of organic products from infestation Mycobionten, characterized in that these organic products active compound combinations according to the invention are added in an effective amount.
  • the active compound combinations according to the invention are particularly effective against the germ Pityrosporum ovale and related germs responsible for the development of dandruff.
  • a preferred embodiment of the present invention are thus anti-dandruff formulations, for example anti-dandruff shampoos.
  • the cosmetic and / or dermatological formulations according to the invention are applied to the skin and / or the hair in a sufficient amount in the manner customary for cosmetics and dermatological agents.
  • cosmetic and dermatological preparations that are in the form of a sunscreen.
  • these additionally contain min. at least one UVA filter, UVB and / or at least one broadband filter and / or at least one inorganic pigment.
  • Cosmetic preparations according to the invention for protecting the skin from UV rays may be in various forms, e.g. Usually used for this type of preparations. So they can e.g. a solution, a water-in-oil (W / O) or oil-in-water (O / W) type emulsion, or a multiple emulsions, such as water-in-oil-in-water (W / O / W), a gel, a hydrodispersion, a solid stick or even an aerosol.
  • the cosmetic preparations according to the invention may contain cosmetic adjuvants such as are commonly used in such preparations, e.g. Preservatives, bactericides, antioxidants, perfumes, antifoaming agents, dyes, pigments which have a coloring effect, thickeners, surface-active substances, emulsifiers, emollients, moisturizing and / or moisturizing substances, fats, oils, powders, waxes or other conventional ingredients of a cosmetic formulation such as alcohols, polyols, polymers, foam stabilizers, electrolytes, organic solvents or silicone derivatives.
  • cosmetic adjuvants such as are commonly used in such preparations, e.g. Preservatives, bactericides, antioxidants, perfumes, antifoaming agents, dyes, pigments which have a coloring effect, thickeners, surface-active substances, emulsifiers, emollients, moisturizing and / or moisturizing substances, fats, oils, powders, waxes or
  • Emulsions are advantageous according to the invention and contain e.g. the said fats, oils, waxes and other fatty substances, as well as water and an emulsifier, as commonly used for such a type of formulation.
  • Gels according to the invention usually contain low C number alcohols, e.g. Ethanol, isopropanol, 1, 2-propanediol, glycerol and water or an above-mentioned oil in the presence of a thickener which is preferably silica or an aluminosilicate in oily-alcoholic gels, in aqueous-alcoholic or alcoholic gels, preferably a polyacrylate.
  • a thickener which is preferably silica or an aluminosilicate in oily-alcoholic gels, in aqueous-alcoholic or alcoholic gels, preferably a polyacrylate.
  • Solid sticks according to the invention contain, for example, natural or synthetic waxes, fatty alcohols or fatty acid esters. Preference is given to lip balms and deodorant sticks ("deodorant sticks").
  • Suitable propellants for inventive, sprayable from aerosol containers cosmetic or dermatological preparations are the usual known volatile, liquefied propellants, such as hydrocarbons (propane, butane, isobutane) suitable, which can be used alone or in mixture with each other. Also, compressed air is advantageous to use.
  • the preparations according to the invention may additionally contain substances which absorb UV radiation in the UVB and UVA range, the total amount of filter substances being e.g. From 0.1% by weight to 50% by weight, preferably from 0.5 to 10% by weight, in particular from 1 to 6% by weight, based on the total weight of the preparation, in order to provide cosmetic preparations, which protect the skin from the entire range of ultraviolet radiation.
  • Cosmetic preparations for the care of the hair are, for example, shampooing agents, preparations which are used to rinse the hair before or after shampooing, before or after the permanent wave treatment, before or after dyeing or discoloring the hair, to make-up preparations or Inserting the hair, preparations for dyeing or decolorizing, a hairdressing and treatment lotion, a hair lacquer or permanent waving agent.
  • the cosmetic preparations contain active ingredients and adjuvants such as are commonly used for this type of preparations for hair care and hair treatment.
  • Adjuvants are preservatives, surface-active substances, foaming inhibitors, emulsifiers, thickeners, fats, oils, waxes, organic solvents, bactericides, perfumes, dyes or pigments, the object of which is to dye the hair or the preparation itself , Electrolytes, preparations against the greasing of the hair.
  • Cosmetic preparations which are a shampoo or a washing, showering or bathing preparation preferably contain at least one anionic, nonionic or amphoteric surfactant or mixtures thereof, active ingredient combinations according to the invention, and auxiliaries as are usually used therefor.
  • Citric acid 0.0050 0 0 0 0 0
  • Polyglyceryl-10 Stearate 0.7 0 1, 8 1 1
  • Carbopol 981 0.5 0.02 0.02 0 0
  • Phenylbenzimidazolesulfonic acid 0 0 0 0 2
  • Ethylhexyl salicylate 0 0 0 0 2
  • Carrageenan (Chondrus Crispus) - - - - - 2
  • the bacterium S. aureus (ATCC 12000) was streaked out of a cryopreserved tube in accordance with EN 12353 on a corresponding agar plate (TSA agar) and incubated at 37 ° C for 24 hours. From the grown bacteria, a second passage was created, which was used in the growth curve.
  • a loop of the bacteria was added to 10ml of diluent and 5g of 4mm diameter glass beads and vortexed for 3 minutes. Subsequently, this bacterial suspension was adjusted to an OD of 0.08 to ensure a microbial count of approximately 5 * 10 7 . This bacterial suspension was then used for the test.
  • the growth curve was performed by TECAN pipetting robot. To this end, 500 ⁇ _ of the drug solutions to be tested and 500 ⁇ of the bacterial suspension were placed in Eppendorf tubes without lid with welded foil in the cooling rack. After 1, 6 and 24 hours at 20 ° C were taken in each case 100 ⁇ _ from the Eppendorf tubes and 800 ⁇ _ neutralizing agent and 100 ⁇ water pipetted (10 '1 - dilution). For the 10 "1 dilution was a 10" 3 dilution prepared ( 990 ⁇ diluent and 10 ⁇ from the 10 "1 dilution). These dilutions were plated out on agar plates using spiral plates.
  • the reduction factor is the factor by which the cell number (CFU) of the test substance is reduced compared to the control.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne des associations de principes actifs contenant a) un ou plusieurs polyols et b) un ou plusieurs acides hydroxamiques physiologiquement acceptables.
EP12808786.3A 2011-12-19 2012-12-14 Associations de principes actifs à base d'un ou de plusieurs polyols et d'un ou de plusieurs acides hydroxamiques physiologiquement acceptables, ainsi que préparations cosmétiques ou dermatologiques contenant de telles associations de principes actifs Withdrawn EP2793816A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102011088934A DE102011088934A1 (de) 2011-12-19 2011-12-19 Wirkstoffkombinationen aus einem oder mehreren Polyolen und einer oder mehreren physiologisch unbedenklichen Hydroxamsäuren, sowie kosmetische oder 10 dermatologische Zubereitungen, solche Wirkstoffkombinationen enthaltend
PCT/EP2012/075582 WO2013092424A2 (fr) 2011-12-19 2012-12-14 Associations de principes actifs à base d'un ou de plusieurs polyols et d'un ou de plusieurs acides hydroxamiques physiologiquement acceptables, ainsi que préparations cosmétiques ou dermatologiques contenant de telles associations de principes actifs

Publications (1)

Publication Number Publication Date
EP2793816A2 true EP2793816A2 (fr) 2014-10-29

Family

ID=47469964

Family Applications (1)

Application Number Title Priority Date Filing Date
EP12808786.3A Withdrawn EP2793816A2 (fr) 2011-12-19 2012-12-14 Associations de principes actifs à base d'un ou de plusieurs polyols et d'un ou de plusieurs acides hydroxamiques physiologiquement acceptables, ainsi que préparations cosmétiques ou dermatologiques contenant de telles associations de principes actifs

Country Status (3)

Country Link
EP (1) EP2793816A2 (fr)
DE (1) DE102011088934A1 (fr)
WO (1) WO2013092424A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102300945B1 (ko) * 2014-12-05 2021-09-10 주식회사 엘지생활건강 폴리글리세린-3을 함유하는 항균 또는 보존용 조성물

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE729204C (de) * 1941-06-15 1942-12-12 Ig Farbenindustrie Ag Desinfektions- und Konservierungsmittel
US3632764A (en) * 1969-12-15 1972-01-04 Millmaster Onyx Corp Alkyl-hydroxamic acids and salts thereof as anti-fungal agents
DE2060764A1 (de) * 1970-12-10 1972-06-22 Henkel & Cie Gmbh Synergistische,antimikrobielle Wirkstoffkombinationen sowie deren Verwendung in antimikrobiellen Mitteln
JPS61126010A (ja) * 1984-11-20 1986-06-13 Lion Corp 口腔用組成物
WO2006029818A2 (fr) * 2004-09-16 2006-03-23 Dsm Ip Assets B.V. Nouvelles compositions cosmetiques
EP3075401B1 (fr) 2007-11-29 2024-04-03 Inolex Investment Corporation Préservation pour cosmétiques, produits de toilette et compositions pharmaceutiques
KR101080155B1 (ko) * 2011-05-24 2011-11-07 (주)뷰티화장품 겔미용팩 조성물 및 그 제조방법

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
None *
See also references of WO2013092424A2 *

Also Published As

Publication number Publication date
DE102011088934A1 (de) 2013-06-20
WO2013092424A3 (fr) 2014-05-08
WO2013092424A2 (fr) 2013-06-27

Similar Documents

Publication Publication Date Title
DE102010007958A1 (de) Wirkstoffkombinationen aus Acylarginaten und quaternären Ammoniumverbindungen
EP2482796A1 (fr) Utilisation de magnolol ou d'honokiol en tant que principes actifs antibactériens, antimycosiques, antiparasitaires ou antiviraux
EP2793820B1 (fr) Utilisation d'une association d'acide sorbique et d'un acide hydroxamique pour combattre les pellicules cappillaires.
EP1157687B1 (fr) Combinaisons d'éthers monoalcoylés de glycerol et d'alcools substitués par des groupements aryles
WO2013092404A2 (fr) Associations de principes actifs à base de piroctone olamine et d'un ou de plusieurs acides hydroxamiques physiologiquement acceptables, et préparations cosmétiques ou dermatologiques contenant de telles associations de principes actifs
DE102011088944A1 (de) Wirkstoffkombinationen aus Silberverbindungen und einer oder mehreren physiologisch unbedenklichen Hydroxamsäure sowie kosmetische oder dermatologischeZubereitungen, solche Wirkstoffkombinationen enthaltend
EP2535040B1 (fr) Combinaisons de substances actives à base d'epsilon-polylysine et d'un ou plusieurs alkanols éthoxylés et/ou propoxylés
KR20210111230A (ko) 폴리글리세린-3을 함유하는 항균 또는 보존용 조성물
EP2717837B1 (fr) Associations de principes actifs contenant la epsilon-poly-lysine (epsilon-poly-lysine) et un ou plusieurs esters, aldéhydes et/ou alcools aromatiques
DE102009050854A1 (de) Verwendung von Menthylethern als antibakterielle, antimycotische oder antivirale Wirkstoffe
WO2013092424A2 (fr) Associations de principes actifs à base d'un ou de plusieurs polyols et d'un ou de plusieurs acides hydroxamiques physiologiquement acceptables, ainsi que préparations cosmétiques ou dermatologiques contenant de telles associations de principes actifs
DE102011077067A1 (de) Wirkstoffkombinationen aus å-Polylysin (Epsilon-Polylysin) und einem odermehreren aromatischen Aldehyden
EP2793814B1 (fr) Associations de principes actifs à base d'un ou de plusieurs alcools aromatiques et d' acide octanohydroxamique, ainsi que préparations cosmétiques ou dermatologiques contenant de telles associations de principes actifs
WO2012168360A2 (fr) Associations de principes actifs à base de ε-polylysine (epsilon-polylysine) et de piroctone olamine et/ou de climbazole
EP1297829A1 (fr) Combinaison de principes actives à base des alcools polyhydriques et d'acides acétique dialkylsubstitués agissant contre des bacteries, des mycoses et des viruses
EP2793815B1 (fr) Utilisation d'une préparation dermatologique comprenant une association de principes actifs d'un ou plusieurs alkyl ethers de glycerol et d'un ou plusieurs acides hydroxamiques physiologiquement sans danger
EP2717838A2 (fr) Combinaisons de principes actifs comprenant de l' e-polylysine (epsilon-polylysine) et un ou plusieurs terpènes
EP1157686A2 (fr) Combinations d'éthers monoalkylés de glycerine et de glycérides d'acides gras
DE102011077055A1 (de) Wirkstoffkombinationen aus å-Polylysin (Epsilon-Polylysin) und einem oder mehreren aromatischen Estern
DE102011077063A1 (de) Wirkstoffkombinationen aus å-Polylysin (Epsilon-Polylysin) und einem oder mehrerenaromatischen Alkoholen
DE102011077077A1 (de) Wirkstoffkombinationen aus Epsilon-Polylysin und einem odermehreren Terpenen
DE102011077075A1 (de) Wirkstoffkombinationen aus Epsilon-Polylysin und einem oder mehreren Alkylglucosiden
DE102011077071A1 (de) Wirkstoffkombinationen aus Epsilon-Polylysin und Climbazol
DE102011077070A1 (de) Wirkstoffkombinationen aus Epsilon-Polylysin und einem oder mehreren Estern mit Terpenstruktur
DE102011077046A1 (de) Wirkstoffkombinationen aus å-Polylysin (Epsilon-Polylysin) und Pirocton Olamin

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20140509

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

RIN1 Information on inventor provided before grant (corrected)

Inventor name: GOEKSEL, HUELYA

Inventor name: KOEHLER, MANUELA

Inventor name: TRAUPE, BERND

Inventor name: FIRYN, ANDREAS

R17P Request for examination filed (corrected)

Effective date: 20141110

RBV Designated contracting states (corrected)

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20151207

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20170927